CLAIMS

1. An ophthalmic composition suitable for ocular injection, comprising

   (i) prednisolone encapsulated in a liposome, wherein the liposome comprises a phospholipid wherein the phospholipid is selected from the group consisting of 1-palmitoyl-2-oleoyl-glycero-3-phosphocholine (POPC)) and 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC);

   wherein the liposome has a diameter of about 100 nm to about 200 nm;

   wherein the liposome is free of added cholesterol and free of PEGylated lipid;

   wherein the prednisolone is present at about 3% to about 6% (w/w) of the liposome, and

   (ii) an aqueous buffer suitable for administration to an eye.

2. The ophthalmic composition of claim 1, wherein the aqueous buffer is a phosphate buffered saline (PBS).

3. The ophthalmic composition of claim 1, wherein the phospholipid is DOPC.

4. The ophthalmic composition of claim 1, wherein the phospholipid is POPC.

5. The ophthalmic composition of claim 1, wherein the liposome releases about 55 wt % or less of prednisolone by about 12 hours, about 65 wt % or less prednisolone at about 24 hours, wherein release is determined by HPLC.

6. The ophthalmic composition of claim 1, wherein the liposome releases about 75 wt % or less of prednisolone at about 36 hours, wherein release is determined by HPLC.

7. The ophthalmic composition of claim 3, wherein leakage of prednisolone from the liposome is less than about 10 wt % of prednisolone at 3 weeks when the composition is stored at 5° C.

8. Use of an ophthalmic composition of claim 1 in the manufacture of a medicament for treating a disease or disorder of the eye in a subject in need thereof, wherein the medicament is to be injected into the ocular region.

9. The use of claim 8, wherein the disease or disorder of the eye is selected from the group consisting of: uveitis, diabetic retinopathy, edema, macular degeneration, and telangitis.

10. The use of claim 9, wherein the disease or disorder of the eye is an edema and the edema is a macular edema.

11. The use of claim 10, wherein the macular edema is choroidal macular edema (CME) or diabetic macular edema (DME).

12. The use of claim 8, wherein subject has post ocular surgical inflammation of the eye.

13. The use of claim 8, wherein the injection is subtenon, peribulbar, intracameral or suprachoroidal.

14. The use of claim 8, wherein the ophthalmic composition is to be administered in a volume of about 0.03 mL to about 0.05 mL.

15. The use of claim 8, wherein the subject has a central retinal vein occlusion (CRVO) or a branch retinal vein occlusion (BRVO).

16. The use of claim 9, wherein the disease or disorder of the eye is macular degeneration and the macular degeneration is age related macular degeneration (ARMD).